Brief: IGM Biosciences Announces Q4 Results

IGM Biosciences

29/03/2022 11:28

March 29 (Reuters) - IGM Biosciences Inc  IGMS.O :
    * CASH AND INVESTMENTS AS OF DECEMBER 31, 2021 WERE $229.5
MILLION, COMPARED TO $366.3 MILLION AS OF DECEMBER 31, 2020
    * QTRLY  LOSS PER SHARE $1.50
    * EXPECTS FULL YEAR GAAP OPERATING EXPENSES OF $250 MILLION
TO
$260 MILLION
    * Q4 EARNINGS PER SHARE VIEW $-1.54 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX5mQyxk 
Further company coverage:  IGMS.O 

 ((Reuters.Briefs@thomsonreuters.com;))